Details of the Drug

General Information of Drug (ID: DMMZSXQ)

Drug Name

Azathioprine

Synonyms

Azamun; Azanin; Azasan; Azathioprin; Azathioprinum; Azathiopurine; Azatioprin; Azatioprina; Azothioprine; Ccucol; Cytostatics; Immuran; Imuran; Imurek; Imurel; Methylnitroimidazolylmercaptopurine; Muran; Azamun [Czech]; Azathioprine sodium; Azatiopr in; A 4638; BW 57322; Azamun (TN); Azasan (TN); Azathioprinum [INN-Latin]; Azatioprina [INN-Spanish]; BW 57-322; Imuran (TN); Imurel (TN); [Methyl(nitroimidazolyl)mercaptopurine]; AI-981/34845012; BW-57-322; Azathioprine (JP15/USP/INN); Azathioprine [USAN:INN:BAN:JAN]; B. W. 57-322; Thiopurine 6-(1-methyl-4-nitroimidazol-5-yl); Azasan, Imuran, Azamun, BW-57-322, NSC-39084, Azathioprine; 6-((1-Methyl-4-nitro-1H-imidazol-5-yl)thio)-1H-purine; 6-((1-Methyl-4-nitroimidazol-5-yl)thio)purine; 6-(1'-Methyl-4'-nitro-5'-imidazolyl)-mercaptopurine; 6-(1'-Methyl-4'-nitro-5'-imidazolyl)mercaptopurine; 6-(1-Methyl-4-nitroimidazol-5-yl)thiopurine; 6-(1-Methyl-4-nitroimidazol-5-ylthio)purin; 6-(1-Methyl-4-nitroimidazol-5-ylthio)purin [Czech]; 6-(1-Methyl-p-nitro-5-imidazolyl)-thiopurine; 6-(1-Methyl-p-nitro-5-imidazolyl)thiopurine; 6-(3-Methyl-5-nitro-3H-imidazol-4-ylsulfanyl)-7H-purine; 6-(3-methyl-5-nitroimidazol-4-yl)sulfanyl-7H-purine; 6-(Methyl-p-nitro-5-imidazolyl)-thiopurine; 6-(Methyl-p-nitro-5-imidazolyl)thiopurine; 6-({4-nitro-1-methyl-1H-imidazol-5-yl}sulfanyl)-7H-purine; 6-1'-Methyl,4'-nitro,5'-imidazolyl mercaptopurine; 6-[(1-Methyl-4-nitroimidazol-5-yl)-thio] purine; 6-[(1-Methyl-4-nitroimidazol-5-yl)thio]purine; 6-[(1-methyl-4-nitro-1H-imidazol-5-yl)sulfanyl]-7H-purine; 6-[(1-methyl-4-nitro-1H-imidazol-5-yl)thio]-1H-Purine; 6-[(1-methyl-4-nitro-1H-imidazol-5-yl)thio]-7H-purine; 6-[(1-methyl-4-nitro-1H-imidazol-5-yl)thio]-9H-purine

Indication

Disease Entry	ICD 11	Status	REF
Organ transplant rejection	NE84	Approved	[1], [2]

Therapeutic Class

Immunosuppressive Agents

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

277.27

Topological Polar Surface Area (xlogp)

0.1

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

Absorption Tmax: The time to maximum plasma concentration (Tmax) is 1-2 h [3]
BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [4]
Bioavailability: 60% of drug becomes completely available to its intended biological destination(s) [5]
Elimination: 1% of drug is excreted from urine in the unchanged form [4]
Half-life: The concentration or amount of drug in body reduced by one-half in 5 hours [3]
Metabolism: The drug is metabolized via thiopurine methyltransferase, 6-thiouric acid by xanthine oxidase, or 6-thiosine-5'-monophosphate by hypoxanthine phosphoribosyltransferase [6]
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 18.03324 micromolar/kg/day [7]
Water Solubility: The ability of drug to dissolve in water is measured as 10 mg/mL [4]

Chemical Identifiers

Formula: C9H7N7O2S
IUPAC Name: 6-(3-methyl-5-nitroimidazol-4-yl)sulfanyl-7H-purine
Canonical SMILES: CN1C=NC(=C1SC2=NC=NC3=C2NC=N3)[N+](=O)[O-]
InChI: InChI=1S/C9H7N7O2S/c1-15-4-14-7(16(17)18)9(15)19-8-5-6(11-2-10-5)12-3-13-8/h2-4H,1H3,(H,10,11,12,13)
InChIKey: LMEKQMALGUDUQG-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 2265
ChEBI ID: CHEBI:2948
CAS Number: 446-86-6
DrugBank ID: DB00993
TTD ID: D07QCE
VARIDT ID: DR00113
INTEDE ID: DR0164
ACDINA ID: D00054

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Amidophosphoribosyltransferase (PPAT)	TTZFTY4	PUR1_HUMAN	Inhibitor	[8], [9]

------------------------------------------------------------------------------------

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[10]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 1A2 (CYP1A2)	DEJGDUW	CP1A2_HUMAN	Substrate	[11]
Glutathione S-transferase mu-1 (GSTM1)	DEYZEJA	GSTM1_HUMAN	Substrate	[12]
Thiopurine methyltransferase (TPMT)	DEFQ8VO	TPMT_HUMAN	Substrate	[13]
Glutathione S-transferase alpha-2 (GSTA2)	DEH49YS	GSTA2_HUMAN	Substrate	[12]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Azathioprine

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Belatacept	DMXLYQF	Moderate	Additive immunosuppressive effects by the combination of Azathioprine and Belatacept.	Transplant rejection [NE84]	[50]
-----------

Coadministration of a Drug Treating the Disease Different from Azathioprine (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Idarubicin	DMM0XGL	Moderate	Additive myelosuppressive effects by the combination of Azathioprine and Idarubicin.	Acute myeloid leukaemia [2A60]	[50]
Siltuximab	DMGEATB	Moderate	Additive immunosuppressive effects by the combination of Azathioprine and Siltuximab.	Anemia [3A00-3A9Z]	[50]
Roflumilast	DMPGHY8	Moderate	Additive immunosuppressive effects by the combination of Azathioprine and Roflumilast.	Asthma [CA23]	[51]
Dupilumab	DMOAD2Y	Moderate	Additive immunosuppressive effects by the combination of Azathioprine and Dupilumab.	Atopic eczema [EA80]	[50]
Lomustine	DMMWSUL	Moderate	Additive myelosuppressive effects by the combination of Azathioprine and Lomustine.	Brain cancer [2A00]	[50]
Eribulin	DM1DX4Q	Moderate	Additive myelosuppressive effects by the combination of Azathioprine and Eribulin.	Breast cancer [2C60-2C6Y]	[50]
Talazoparib	DM1KS78	Moderate	Additive immunosuppressive effects by the combination of Azathioprine and Talazoparib.	Breast cancer [2C60-2C6Y]	[50]
Ixabepilone	DM2OZ3G	Moderate	Additive immunosuppressive effects by the combination of Azathioprine and Ixabepilone.	Breast cancer [2C60-2C6Y]	[50]
LY2835219	DM93VBZ	Moderate	Additive myelosuppressive effects by the combination of Azathioprine and LY2835219.	Breast cancer [2C60-2C6Y]	[50]
Pralatrexate	DMAO80I	Moderate	Additive myelosuppressive effects by the combination of Azathioprine and Pralatrexate.	Breast cancer [2C60-2C6Y]	[50]
Palbociclib	DMD7L94	Moderate	Additive myelosuppressive effects by the combination of Azathioprine and Palbociclib.	Breast cancer [2C60-2C6Y]	[50]
Thiotepa	DMIZKOP	Moderate	Additive immunosuppressive effects by the combination of Azathioprine and Thiotepa.	Breast cancer [2C60-2C6Y]	[50]
Cabazitaxel	DMPAZHC	Moderate	Additive immunosuppressive effects by the combination of Azathioprine and Cabazitaxel.	Breast cancer [2C60-2C6Y]	[50]
Bosutinib	DMTI8YE	Moderate	Additive myelosuppressive effects by the combination of Azathioprine and Bosutinib.	Breast cancer [2C60-2C6Y]	[50]
Anisindione	DM2C48U	Moderate	Antagonize the effect of Azathioprine when combined with Anisindione.	Coagulation defect [3B10]	[52]
Aflibercept	DMT3D5I	Moderate	Additive immunosuppressive effects by the combination of Azathioprine and Aflibercept.	Colorectal cancer [2B91]	[50]
Capecitabine	DMTS85L	Moderate	Additive immunosuppressive effects by the combination of Azathioprine and Capecitabine.	Colorectal cancer [2B91]	[50]
Mycophenolic acid	DMU65NK	Moderate	Additive immunosuppressive effects by the combination of Azathioprine and Mycophenolic acid.	Crohn disease [DD70]	[53]
Polatuzumab vedotin	DMF6Y0L	Moderate	Additive immunosuppressive effects by the combination of Azathioprine and Polatuzumab vedotin.	Diffuse large B-cell lymphoma [2A81]	[50]
Axicabtagene ciloleucel	DMYHN59	Moderate	Additive myelosuppressive effects by the combination of Azathioprine and Axicabtagene ciloleucel.	Diffuse large B-cell lymphoma [2A81]	[50]
Flucytosine	DM13VTW	Moderate	Additive myelosuppressive effects by the combination of Azathioprine and Flucytosine.	Endocarditis [BB40-BA42]	[50]
Bay 80-6946	DMLOS5R	Moderate	Additive myelosuppressive effects by the combination of Azathioprine and Bay 80-6946.	Follicular lymphoma [2A80]	[50]
Avapritinib	DMK2GZX	Moderate	Additive immunosuppressive effects by the combination of Azathioprine and Avapritinib.	Gastrointestinal stromal tumour [2B5B]	[50]
Colchicine	DM2POTE	Moderate	Additive myelosuppressive effects by the combination of Azathioprine and Colchicine.	Gout [FA25]	[50]
177Lu-DOTATATE	DMT8GVU	Moderate	Additive myelosuppressive effects by the combination of Azathioprine and 177Lu-DOTATATE.	Hepatitis virus infection [1E50-1E51]	[50]
Procarbazine	DMIK367	Moderate	Additive immunosuppressive effects by the combination of Azathioprine and Procarbazine.	Hodgkin lymphoma [2B30]	[50]
Brentuximab vedotin	DMWLC57	Moderate	Additive myelosuppressive effects by the combination of Azathioprine and Brentuximab vedotin.	Hodgkin lymphoma [2B30]	[50]
Teriflunomide	DMQ2FKJ	Major	Additive immunosuppressive effects by the combination of Azathioprine and Teriflunomide.	Hyper-lipoproteinaemia [5C80]	[54]
Febuxostat	DMDEXQ0	Major	Decreased metabolism of Azathioprine caused by Febuxostat mediated inhibition of non-CYP450 enzyme.	Inborn purine/pyrimidine/nucleotide metabolism error [5C55]	[55]
Balsalazide	DMO091F	Moderate	Decreased metabolism of Azathioprine caused by Balsalazide mediated inhibition of non-CYP450 enzyme.	Indeterminate colitis [DD72]	[56]
Olaratumab	DMNYOIX	Moderate	Additive immunosuppressive effects by the combination of Azathioprine and Olaratumab.	Kaposi sarcoma [2B57]	[50]
Nelarabine	DMB6VEG	Moderate	Additive immunosuppressive effects by the combination of Azathioprine and Nelarabine.	Leukaemia [2A60-2B33]	[50]
Denosumab	DMNI0KO	Moderate	Additive myelosuppressive effects by the combination of Azathioprine and Denosumab.	Low bone mass disorder [FB83]	[57]
Brigatinib	DM7W94S	Moderate	Additive immunosuppressive effects by the combination of Azathioprine and Brigatinib.	Lung cancer [2C25]	[50]
Lurbinectedin	DMEFRTZ	Moderate	Additive immunosuppressive effects by the combination of Azathioprine and Lurbinectedin.	Lung cancer [2C25]	[50]
Osimertinib	DMRJLAT	Moderate	Additive immunosuppressive effects by the combination of Azathioprine and Osimertinib.	Lung cancer [2C25]	[50]
Belimumab	DM3OBQF	Moderate	Additive immunosuppressive effects by the combination of Azathioprine and Belimumab.	Lupus erythematosus [4A40]	[50]
Primaquine	DMWQ16I	Moderate	Additive myelosuppressive effects by the combination of Azathioprine and Primaquine.	Malaria [1F40-1F45]	[50]
Inotuzumab ozogamicin	DMAC130	Moderate	Additive immunosuppressive effects by the combination of Azathioprine and Inotuzumab ozogamicin.	Malignant haematopoietic neoplasm [2B33]	[50]
Fludarabine	DMVRLT7	Moderate	Additive myelosuppressive effects by the combination of Azathioprine and Fludarabine.	Malignant haematopoietic neoplasm [2B33]	[50]
Ofatumumab	DM295PR	Moderate	Additive myelosuppressive effects by the combination of Azathioprine and Ofatumumab.	Mature B-cell leukaemia [2A82]	[50]
Obinutuzumab	DM3BVAE	Moderate	Additive myelosuppressive effects by the combination of Azathioprine and Obinutuzumab.	Mature B-cell leukaemia [2A82]	[50]
Idelalisib	DM602WT	Moderate	Additive myelosuppressive effects by the combination of Azathioprine and Idelalisib.	Mature B-cell leukaemia [2A82]	[50]
GDC-0199	DMH0QKA	Moderate	Additive immunosuppressive effects by the combination of Azathioprine and GDC-0199.	Mature B-cell leukaemia [2A82]	[50]
IPI-145	DMWA24P	Moderate	Additive immunosuppressive effects by the combination of Azathioprine and IPI-145.	Mature B-cell leukaemia [2A82]	[50]
Blinatumomab	DMGECIJ	Moderate	Additive immunosuppressive effects by the combination of Azathioprine and Blinatumomab.	Mature B-cell lymphoma [2A85]	[50]
Ibrutinib	DMHZCPO	Moderate	Additive immunosuppressive effects by the combination of Azathioprine and Ibrutinib.	Mature B-cell lymphoma [2A85]	[50]
Tisagenlecleucel	DMM9BJD	Moderate	Additive immunosuppressive effects by the combination of Azathioprine and Tisagenlecleucel.	Mature B-cell lymphoma [2A85]	[50]
Mercaptopurine	DMTM2IK	Major	Additive immunosuppressive effects by the combination of Azathioprine and Mercaptopurine.	Mature B-cell lymphoma [2A85]	[58]
Ponatinib	DMYGJQO	Moderate	Additive immunosuppressive effects by the combination of Azathioprine and Ponatinib.	Mature B-cell lymphoma [2A85]	[50]
Carfilzomib	DM48K0X	Moderate	Additive myelosuppressive effects by the combination of Azathioprine and Carfilzomib.	Multiple myeloma [2A83]	[50]
Panobinostat	DM58WKG	Moderate	Additive immunosuppressive effects by the combination of Azathioprine and Panobinostat.	Multiple myeloma [2A83]	[50]
Thalidomide	DM70BU5	Moderate	Additive myelosuppressive effects by the combination of Azathioprine and Thalidomide.	Multiple myeloma [2A83]	[50]
Selinexor	DMBD4K3	Moderate	Additive myelosuppressive effects by the combination of Azathioprine and Selinexor.	Multiple myeloma [2A83]	[50]
Belantamab mafodotin	DMBT3AI	Moderate	Additive immunosuppressive effects by the combination of Azathioprine and Belantamab mafodotin.	Multiple myeloma [2A83]	[50]
Elotuzumab	DMEYHG9	Moderate	Additive immunosuppressive effects by the combination of Azathioprine and Elotuzumab.	Multiple myeloma [2A83]	[50]
Daratumumab	DMKCIUZ	Moderate	Additive myelosuppressive effects by the combination of Azathioprine and Daratumumab.	Multiple myeloma [2A83]	[50]
Melphalan	DMOLNHF	Moderate	Additive immunosuppressive effects by the combination of Azathioprine and Melphalan.	Multiple myeloma [2A83]	[50]
Tecfidera	DM2OVDT	Moderate	Additive immunosuppressive effects by the combination of Azathioprine and Tecfidera.	Multiple sclerosis [8A40]	[50]
Siponimod	DM2R86O	Major	Additive immunosuppressive effects by the combination of Azathioprine and Siponimod.	Multiple sclerosis [8A40]	[50]
Fingolimod	DM5JVAN	Major	Additive immunosuppressive effects by the combination of Azathioprine and Fingolimod.	Multiple sclerosis [8A40]	[59]
Ocrelizumab	DMEZ2KH	Moderate	Additive immunosuppressive effects by the combination of Azathioprine and Ocrelizumab.	Multiple sclerosis [8A40]	[50]
Ozanimod	DMT6AM2	Major	Additive immunosuppressive effects by the combination of Azathioprine and Ozanimod.	Multiple sclerosis [8A40]	[51]
Romidepsin	DMT5GNL	Moderate	Additive immunosuppressive effects by the combination of Azathioprine and Romidepsin.	Mycosis fungoides [2B01]	[50]
Decitabine	DMQL8XJ	Moderate	Additive immunosuppressive effects by the combination of Azathioprine and Decitabine.	Myelodysplastic syndrome [2A37]	[50]
Nilotinib	DM7HXWT	Moderate	Additive immunosuppressive effects by the combination of Azathioprine and Nilotinib.	Myeloproliferative neoplasm [2A20]	[50]
Ruxolitinib	DM7Q98D	Moderate	Additive immunosuppressive effects by the combination of Azathioprine and Ruxolitinib.	Myeloproliferative neoplasm [2A20]	[50]
Dasatinib	DMJV2EK	Moderate	Additive immunosuppressive effects by the combination of Azathioprine and Dasatinib.	Myeloproliferative neoplasm [2A20]	[50]
Hydroxyurea	DMOQVU9	Moderate	Additive myelosuppressive effects by the combination of Azathioprine and Hydroxyurea.	Myeloproliferative neoplasm [2A20]	[50]
Omacetaxine mepesuccinate	DMPU2WX	Moderate	Additive immunosuppressive effects by the combination of Azathioprine and Omacetaxine mepesuccinate.	Myeloproliferative neoplasm [2A20]	[50]
Busulfan	DMXYJ9C	Moderate	Additive immunosuppressive effects by the combination of Azathioprine and Busulfan.	Myeloproliferative neoplasm [2A20]	[50]
Inebilizumab	DMI0RHA	Moderate	Additive immunosuppressive effects by the combination of Azathioprine and Inebilizumab.	Nervous system paraneoplastic/autoimmune disorder [8E4A]	[50]
Atezolizumab	DMMF8U0	Moderate	Additive immunosuppressive effects by the combination of Azathioprine and Atezolizumab.	Non-small cell lung cancer [2C25]	[50]
Olaparib	DM8QB1D	Moderate	Additive immunosuppressive effects by the combination of Azathioprine and Olaparib.	Ovarian cancer [2C73]	[50]
Rucaparib	DM9PVX8	Moderate	Additive myelosuppressive effects by the combination of Azathioprine and Rucaparib.	Ovarian cancer [2C73]	[50]
MK-4827	DMLYGH4	Moderate	Additive myelosuppressive effects by the combination of Azathioprine and MK-4827.	Ovarian cancer [2C73]	[50]
Topotecan	DMP6G8T	Moderate	Additive myelosuppressive effects by the combination of Azathioprine and Topotecan.	Ovarian cancer [2C73]	[50]
Tildrakizumab	DMLW9HG	Moderate	Additive immunosuppressive effects by the combination of Azathioprine and Tildrakizumab.	Psoriasis [EA90]	[50]
Risankizumab	DMM32GT	Moderate	Additive immunosuppressive effects by the combination of Azathioprine and Risankizumab.	Psoriasis [EA90]	[50]
Ixekizumab	DMXW92T	Moderate	Additive immunosuppressive effects by the combination of Azathioprine and Ixekizumab.	Psoriasis [EA90]	[50]
Everolimus	DM8X2EH	Moderate	Additive myelosuppressive effects by the combination of Azathioprine and Everolimus.	Renal cell carcinoma [2C90]	[50]
Temsirolimus	DMS104F	Moderate	Additive myelosuppressive effects by the combination of Azathioprine and Temsirolimus.	Renal cell carcinoma [2C90]	[50]
Baricitinib	DM4ONW5	Major	Additive immunosuppressive effects by the combination of Azathioprine and Baricitinib.	Rheumatoid arthritis [FA20]	[50]
Tocilizumab	DM7J6OR	Moderate	Additive immunosuppressive effects by the combination of Azathioprine and Tocilizumab.	Rheumatoid arthritis [FA20]	[50]
Canakinumab	DM8HLO5	Moderate	Additive immunosuppressive effects by the combination of Azathioprine and Canakinumab.	Rheumatoid arthritis [FA20]	[60]
Rilonacept	DMGLUQS	Moderate	Additive immunosuppressive effects by the combination of Azathioprine and Rilonacept.	Rheumatoid arthritis [FA20]	[60]
Golimumab	DMHZV7X	Major	Additive immunosuppressive effects by the combination of Azathioprine and Golimumab.	Rheumatoid arthritis [FA20]	[61]
Leflunomide	DMR8ONJ	Major	Additive immunosuppressive effects by the combination of Azathioprine and Leflunomide.	Rheumatoid arthritis [FA20]	[51]
Abatacept	DMSA8RU	Moderate	Additive immunosuppressive effects by the combination of Azathioprine and Abatacept.	Rheumatoid arthritis [FA20]	[50]
Anthrax vaccine	DM9GSWY	Moderate	Antagonize the effect of Azathioprine when combined with Anthrax vaccine.	Sepsis [1G40-1G41]	[62]
Mogamulizumab	DMISH0Z	Moderate	Additive immunosuppressive effects by the combination of Azathioprine and Mogamulizumab.	Sezary syndrome [2B02]	[50]
PDX-101	DM6OC53	Moderate	Additive immunosuppressive effects by the combination of Azathioprine and PDX-101.	Solid tumour/cancer [2A00-2F9Z]	[50]
Ifosfamide	DMCT3I8	Moderate	Additive immunosuppressive effects by the combination of Azathioprine and Ifosfamide.	Solid tumour/cancer [2A00-2F9Z]	[50]
Docetaxel	DMDI269	Moderate	Additive immunosuppressive effects by the combination of Azathioprine and Docetaxel.	Solid tumour/cancer [2A00-2F9Z]	[50]
Trabectedin	DMG3Y89	Moderate	Additive myelosuppressive effects by the combination of Azathioprine and Trabectedin.	Solid tumour/cancer [2A00-2F9Z]	[50]
Mitoxantrone	DMM39BF	Moderate	Additive myelosuppressive effects by the combination of Azathioprine and Mitoxantrone.	Solid tumour/cancer [2A00-2F9Z]	[50]
LEE011	DMMX75K	Moderate	Additive myelosuppressive effects by the combination of Azathioprine and LEE011.	Solid tumour/cancer [2A00-2F9Z]	[50]
Taxol	DMUOT9V	Moderate	Additive myelosuppressive effects by the combination of Azathioprine and Taxol.	Solid tumour/cancer [2A00-2F9Z]	[50]
Doxorubicin	DMVP5YE	Moderate	Additive myelosuppressive effects by the combination of Azathioprine and Doxorubicin.	Solid tumour/cancer [2A00-2F9Z]	[50]
Pomalidomide	DMTGBAX	Moderate	Additive myelosuppressive effects by the combination of Azathioprine and Pomalidomide.	Systemic sclerosis [4A42]	[50]
Plicamycin	DM7C8YV	Moderate	Additive myelosuppressive effects by the combination of Azathioprine and Plicamycin.	Testicular cancer [2C80]	[50]
Deferiprone	DMS2M7O	Major	Additive myelosuppressive effects by the combination of Azathioprine and Deferiprone.	Thalassaemia [3A50]	[50]
Trimetrexate	DMDEA85	Moderate	Additive immunosuppressive effects by the combination of Azathioprine and Trimetrexate.	Toxoplasmosis [1F57]	[50]
Olsalazine	DMZW9HA	Moderate	Decreased metabolism of Azathioprine caused by Olsalazine mediated inhibition of non-CYP450 enzyme.	Ulcerative colitis [DD71]	[56]
Durvalumab	DM4PVDY	Moderate	Additive immunosuppressive effects by the combination of Azathioprine and Durvalumab.	Ureteral cancer [2C92]	[50]
Ganciclovir	DM1MBYQ	Moderate	Additive myelosuppressive effects by the combination of Azathioprine and Ganciclovir.	Virus infection [1A24-1D9Z]	[50]
Valganciclovir	DMS2IUH	Moderate	Additive myelosuppressive effects by the combination of Azathioprine and Valganciclovir.	Virus infection [1A24-1D9Z]	[50]
-----------


⏷ Show the Full List of 107 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Stearic acid	E00079	5281	Emulsifying agent; Solubilizing agent; Viscosity-controlling agent; lubricant
Beta-D-lactose	E00099	6134	Diluent; Dry powder inhaler carrier; Lyophilization aid
Carmellose sodium	E00625	Not Available	Disintegrant
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate	E00208	11177	lubricant
Povidone	E00667	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
--------------------


⏷ Show the Full List of 6 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Azathioprine 100 mg tablet	100 mg	Oral Tablet	Oral
Azathioprine 50 mg tablet	50 mg	Oral Tablet	Oral
Azathioprine 75 mg tablet	75 mg	Oral Tablet	Oral
Azathioprine 25 mg tablet	25 mg	Oral Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7120).
2	Emerging drugs for idiopathic thrombocytopenic purpura in adults. Expert Opin Emerg Drugs. 2008 Jun;13(2):237-54.
3	FDA Approved Drug Products: Imuran Azathioprine Oral Tablets
4	BDDCS applied to over 900 drugs
5	Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
6	Prasanta Raghab Mohapatra, Deepak Aggarwal: Carbocisteine for acute exacerbations of COPD . 2008 Nov 8;372(9650):1630-1631.
7	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
8	IMPDH activity in thiopurine-treated patients with inflammatory bowel disease - relation to TPMT activity and metabolite concentrations. Br J Clin Pharmacol. 2008 Jan;65(1):69-77.
9	Immunosuppressive drugs and renal transplantation. G Ital Nefrol. 2005 Nov-Dec;22 Suppl 33:S76-9.
10	Caco-2 permeability, P-glycoprotein transport ratios and brain penetration of heterocyclic drugs. Int J Pharm. 2003 Sep 16;263(1-2):113-22.
11	Brassica vegetables increase and apiaceous vegetables decrease cytochrome P450 1A2 activity in humans: changes in caffeine metabolite ratios in response to controlled vegetable diets. Carcinogenesis. 2000 Jun;21(6):1157-62.
12	PharmGKB: A worldwide resource for pharmacogenomic information. Wiley Interdiscip Rev Syst Biol Med. 2018 Jul;10(4):e1417. (ID: PA2040)
13	Nodular regenerative liver hyperplasia as a complication of azathioprine-containing immunosuppressive treatment for Crohn's disease. Immunopharmacol Immunotoxicol. 2011 Jun;33(2):398-402.
14	Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
15	Effects of polyunsaturated fatty acids on prostaglandin synthesis and cyclooxygenase-mediated DNA adduct formation by heterocyclic aromatic amines in human adenocarcinoma colon cells. Mol Carcinog. 2004 Jul;40(3):180-8.
16	Endoxifen and other metabolites of tamoxifen inhibit human hydroxysteroid sulfotransferase 2A1 (hSULT2A1). Drug Metab Dispos. 2014 Nov;42(11):1843-50.
17	Cytochrome P450 1A2 (CYP1A2) activity and risk factors for breast cancer: a cross-sectional study. Breast Cancer Res. 2004;6(4):R352-65.
18	PharmGKB summary: pathways of acetaminophen metabolism at the therapeutic versus toxic doses. Pharmacogenet Genomics. 2015 Aug;25(8):416-26.
19	The effect of apigenin on pharmacokinetics of imatinib and its metabolite N-desmethyl imatinib in rats. Biomed Res Int. 2013;2013:789184.
20	Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
21	The influence of metabolic gene polymorphisms on urinary 1-hydroxypyrene concentrations in Chinese coke oven workers. Sci Total Environ. 2007 Aug 1;381(1-3):38-46.
22	Identification of P450 enzymes involved in metabolism of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1993 Sep;348(3):332-7.
23	Metabolism and metabolic inhibition of xanthotoxol in human liver microsomes. Evid Based Complement Alternat Med. 2016;2016:5416509.
24	Genetics of rheumatoid arthritis. Mayo Clin Proc. 2006 Jan;81(1):94-101.
25	Polymorphism of estrogen metabolism genes and cataract. Med Hypotheses. 2004;63(3):494-7.
26	Influence of estradiol-17 beta and progesterone on catechol-O-methyltransferase and monoamine oxidase activities in uterine artery and myometrium of ovariectomized pigs. Arch Vet Pol. 1993;33(1-2):29-37.
27	The degree of myelosuppression during maintenance therapy of adolescents with B-lineage intermediate risk acute lymphoblastic leukemia predicts risk of relapse. Leukemia. 2010 Apr;24(4):715-20.
28	Histamine-N-methyl transferase polymorphism and risk for multiple sclerosis. Eur J Neurol. 2010 Feb;17(2):335-8.
29	Ascorbic acid inhibits spinal meningeal catechol-o-methyl transferase in vitro, markedly increasing epinephrine bioavailability. Anesthesiology. 1997 Feb;86(2):405-9.
30	Cefazolin administration and 2-methyl-1,3,4-thiadiazole-5-thiol in human tissue: possible relationship to hypoprothrombinemia. Drug Metab Dispos. 2002 Oct;30(10):1123-8.
31	Adrenal catecholamines and their metabolism in the vitamin A deficient rat. Ann Nutr Metab. 1983;27(3):220-7.
32	Reduced 3-O-methyl-dopa levels in OCD patients and their unaffected parents is associated with the low activity M158 COMT allele. Am J Med Genet B Neuropsychiatr Genet. 2010 Mar 5;153B(2):542-548.
33	Usefulness of thiopurine methyltransferase and thiopurine metabolite analysis in clinical practice in patients with inflammatory bowel diseases. Acta Gastroenterol Belg. 2010 Jul-Sep;73(3):331-5.
34	Endothelial cells do not express GSTA1: potential relevance to busulfan-mediated endothelial damage during haematopoietic stem cell transplantation. Eur J Haematol. 2008 Apr;80(4):299-302.
35	Glutathione S-transferase genetic polymorphisms and individual sensitivity to the ototoxic effect of cisplatin. Anticancer Drugs. 2000 Sep;11(8):639-43.
36	PharmGKB: A worldwide resource for pharmacogenomic information. Wiley Interdiscip Rev Syst Biol Med. 2018 Jul;10(4):e1417. (ID: PA150642262)
37	Busulfan conjugation by glutathione S-transferases alpha, mu, and pi. Drug Metab Dispos. 1996 Sep;24(9):1015-9.
38	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
39	MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
40	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
41	Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
42	Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
43	Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
44	Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
45	6-mercaptopurine (6-MP) induces p53-mediated apoptosis of neural progenitor cells in the developing fetal rodent brain. Neurotoxicol Teratol. 2009 Jul-Aug;31(4):198-202.
46	Structure-activity relationships for inhibition of inosine monophosphate dehydrogenase and differentiation induction of K562 cells among the mycoph... Bioorg Med Chem. 2010 Nov 15;18(22):8106-11.
47	Dual inhibitors of inosine monophosphate dehydrogenase and histone deacetylases for cancer treatment. J Med Chem. 2007 Dec 27;50(26):6685-91.
48	Bis(sulfonamide) isosters of mycophenolic adenine dinucleotide analogues: inhibition of inosine monophosphate dehydrogenase. Bioorg Med Chem. 2008 Aug 1;16(15):7462-9.
49	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
50	Cerner Multum, Inc. "Australian Product Information.".
51	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
52	Havrda DE, Rathbun S, Scheid D "A case report of warfarin resistance due to azathioprine and review of the literature." Pharmacotherpy 21 (2001): 355-7. [PMID: 11253860]
53	Product Information. CellCept (mycophenolate mofetil). Roche Laboratories, Nutley, NJ.
54	Product Information. Arava (leflunomide). Hoechst Marion-Roussel Inc, Kansas City, MO.
55	Product Information. Uloric (febuxostat). Takeda Pharmaceuticals America, Lincolnshire, IL.
56	Lewis LD, Benin A, Szumlanski CL, et al. "Olsalazine and 6-mercaptopurine-related bone marrow suppression: a possible drug-drug interaction." Clin Pharmacol Ther 62 (1997): 464-75. [PMID: 9357398]
57	Product Information. Prolia (denosumab). Amgen USA, Thousand Oaks, CA.
58	Petit E, Langouet S, Akhdar H, Nicolas-Nicolaz C, Guillouzo A, Morel F. Differential toxic effects of azathioprine, 6-mercaptopurine and 6-thioguanine on human hepatocytes. Toxicol In Vitro. 2008;22(3):632-642. [PMID: 18222062]
59	Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
60	Product Information. Arcalyst (rilonacept). Regeneron Pharmaceuticals Inc, Tarrytown, NY.
61	Product Information. Cimzia (certolizumab). UCB Pharma Inc, Smyrna, GA.
62	CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18. [PMID: 20300058]